a2129 10g guanidinoethyl sulfonate mce  (MedChemExpress)

Journal: Journal of Diabetes

Article Title: Taurine Alleviates Pancreatic β‐Cell Senescence by Inhibition of p53 Pathway

doi: 10.1111/1753-0407.70100

Figure Lengend Snippet: β‐cells acquire taurine through Slc6a6‐mediated uptake. (A) QPCR analysis of taurine biosynthesis related genes and its transporter Slc6a6 in MIN6 cells and mouse hepatocytes. The results are presented as relative levels over respective gene expression in mouse hepatocytes. ( n = 4). (B, C) MIN6 cells were transfected with siRNA against Scramble or Slc6a6 for 24 h, followed by treatment with taurine (100 μM) or vehicle for 24 h. (B) Immunoblotting analysis of SLC6A6 protein level in each group. ( n = 3). (C) Intracellular taurine levels in the transfected MIN6 cells. ( n = 4). (D) MIN6 cells were pre‐treated with non‐FBS culture medium. The cells were then treated with taurine (100 μM) for 24 h, followed by treatment with SLC6A6 inhibitor (SLC6A6i) (100 μM) or vehicle for 30 min. Intracellular taurine concentration was measured by LC–MS/MS. ( n = 3). All results are presented as mean ± SEM. Significance was determined using two‐tailed independent student's t ‐test. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: For experiments, β‐cells or isolated islets were seeded in appropriate culture vessels (plates or dishes) and allowed to attach and grow for 16 h before treatment with various agents, including taurine (100 μM, Beyotime, Cat#ST1686), hypotaurine (100 μM, MCE, Cat#HY‐100803), SLC6A6 inhibitor taurocyamine (100 μM, MCE, Cat#HY‐113329), doxorubicin (200 nM, MCE, Cat#HY‐15142A), or TNF‐α (20 ng/mL, Abcam, Cat#ab259410) for 24–48 h as indicated in each figure legend.

Techniques: Gene Expression, Transfection, Western Blot, Concentration Assay, Liquid Chromatography with Mass Spectroscopy, Two Tailed Test

Journal: Journal of Diabetes

Article Title: Taurine Alleviates Pancreatic β‐Cell Senescence by Inhibition of p53 Pathway

doi: 10.1111/1753-0407.70100

Figure Lengend Snippet: Dynamics of taurine transporter SLC6A6 in pancreatic islets show elevation during natural aging and a significant decrease in diabetic humans. (A) Expression of SLC6A6 and taurine biosynthesis related genes in islets from young (< 35 years, n = 13), aged (> 60 years) healthy ( n = 14) and aged diabetic (DM, n = 4) human donors (dataset accession: EGAS00001007241). (B) Pancreatic islets were isolated form young, aged healthy, and aged diabetic male human donors. QPCR analysis of genes related to taurine biosynthesis. ( n = 5). (C) Representative immunohistochemistry (IHC) staining images of SLC6A6 in pancreatic sections of young, aged healthy, and aged diabetic male human donors, along with the relative SLC6A6 intensity (right panel). ( n = 5). (Scale bar: 100 μm). All results are presented as mean ± SEM. Significance was determined using one‐way ANOVA with Tukey correction. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: For experiments, β‐cells or isolated islets were seeded in appropriate culture vessels (plates or dishes) and allowed to attach and grow for 16 h before treatment with various agents, including taurine (100 μM, Beyotime, Cat#ST1686), hypotaurine (100 μM, MCE, Cat#HY‐100803), SLC6A6 inhibitor taurocyamine (100 μM, MCE, Cat#HY‐113329), doxorubicin (200 nM, MCE, Cat#HY‐15142A), or TNF‐α (20 ng/mL, Abcam, Cat#ab259410) for 24–48 h as indicated in each figure legend.

Techniques: Expressing, Isolation, Immunohistochemistry

Journal: Journal of Diabetes

Article Title: Taurine Alleviates Pancreatic β‐Cell Senescence by Inhibition of p53 Pathway

doi: 10.1111/1753-0407.70100

Figure Lengend Snippet: The protective effects of taurine against β‐cell senescence depend on its transporter SLC6A6. (A, B) MIN6 cells were pre‐treated with the SLC6A6 inhibitor (SLC6A6i) (100 μM) or vehicle for 30 min, followed by treatment with taurine (100 μM) and doxorubicin (200 nM) or vehicle for 24 h in non‐FBS culture medium. The intracellular taurine concentration was then measured by LC–MS/MS. ( n = 3). (B) Immunoblotting analysis of p53 and p21 in each group. (C–F) MIN6 cells were pre‐treated with doxorubicin (200 nM). The cells were then transfected with siRNA against Scramble or Slc6a6 for 24 h, followed by treatment with taurine (100 μM) or vehicle for 24 h. (C) Immunoblotting analysis of SLC6A6, p53, and p21 in each group. ( n = 3). (D) QPCR analysis of gene expressions related to senescence in each group ( n = 4). (E) QPCR analysis of the genes related to β‐cell specific SASP in each group. ( n = 4). (F) QPCR analysis of genes related to inflammation and apoptosis. ( n = 4). All results are presented as mean ± SEM. Significance was determined using two‐way ANOVA with Tukey correction. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: For experiments, β‐cells or isolated islets were seeded in appropriate culture vessels (plates or dishes) and allowed to attach and grow for 16 h before treatment with various agents, including taurine (100 μM, Beyotime, Cat#ST1686), hypotaurine (100 μM, MCE, Cat#HY‐100803), SLC6A6 inhibitor taurocyamine (100 μM, MCE, Cat#HY‐113329), doxorubicin (200 nM, MCE, Cat#HY‐15142A), or TNF‐α (20 ng/mL, Abcam, Cat#ab259410) for 24–48 h as indicated in each figure legend.

Techniques: Concentration Assay, Liquid Chromatography with Mass Spectroscopy, Western Blot, Transfection